Interim Comment Form: Preview and Dialogue

Jessica Simpson, M.P.H. March 29, 2022





#### **Disclaimer**



- ▶ The following images are design mock-ups NOT the actual form
- ▶ The final look and feel may be slightly different
- Please disregard dates and document status these are examples only, NOT actual PF documents
- This is the first structured comment form for PF. It is designed within current constraints, taking into account as much user feedback as possible.

# Updates coming to commenting



#### Comment form, saving, printing, accessing drafts

- A new comment form is being implemented
  - CC line
  - Structured
  - Identification of submitter
  - Categories of comments
- ▶ When using the comment form you'll be able to save, print, or submit your comment
- Comments— saved or submitted— will be accessible from the dashboard


# **Comment form overview**




FORUM COMMENTING OPEN 01-Nov-2021 to 31-Jan-2022				
Document Tools (	☐ BOOKMARK ☐ CREATE ALERT	CROSS-REF MEMAIL LINK PRINT PAGE		
	Draft/Send Comments	REFERENCE STANDARDS		
HISTORY CONTENTS SUPPORT	Daruna To: sns@usp.org Document: Darunavir Oral Suspension - PF 47(6)	a new monograph based on validated methods of analysis is		
SHOW OLDER VERSIONS	1. The bra * Indicates required field. 2. The The	on analyses performed with the Zorbax Rapid Resolution SB-C8 ed with the YMC-Pack Pro C18 brand of column with L1 packing.		
FORUM PF 47(6) 01-Nov-2021 to 31-Jan-2022  Commenting open for -55 more days	CC: (SM1: S Corresp			
☐ Submit Comment	Subject:	Revision To		
	Add the fo  ADar  Who are you submitting these comments on behalf of ? *  Myself			
	DEFINITIO Organization Darunavir	and NMT 110.0% of the labeled amount of darunavir (C <sub>27</sub> H <sub>37</sub> N <sub>3</sub> O <sub>7</sub> S). Revision Ju		
	Public posting of comments: *  • A. Ther  • B. The L  • No	ard solution, as obtained in the Assay.  rd solution, as obtained in the Assay.		
	ASSAY Disclaimer:			
	Solution Solution Solution Solution			
	Save Comment Print Send Comment Cancel			

### Who are comments submitted on behalf of








We want your feedback on this at the end


# New options for confidentiality and support






#### Main comments






# Different specifications and attachments





#### **Comments on dashboard**





# **Accessing comments**




#### My Resources

DOCUMENT \$	COMMENTING STATUS	COMMENTING DATE $\div$	PUBLICATION	SUBMISSION STATUS 💠	LAST MODIFIED $\Rightarrow$
Bromelain PF 47(6)	Commenting Open	01-Nov-2021 to 31-Jan- 2022	PF 47(6)	Draft	28-Mar-2022
Norflurane PF 47(6)	Commenting Open	01-Nov-2021 to 31-Jan- 2022	PF 47(6)	Draft	28-Mar-202
Bromelain PF 47(6)	Commenting Open	01-Nov-2021 to 31-Jan- 2022	PF 47(6)	Draft	28-Mar-2022
Polyethylene Glycol 30 Dipolyhydroxystearate 5 PF 47(6)	Commenting Open	01-Nov-2021 to 31-Jan- 2022	PF 47(6)	Submitted	24-Mar-2022
Bromelain PF 47(6)	Commenting Open	01-Nov-2021 to 31-Jan- 2022	PF 47(6)	Draft	24-Mar-2022
⟨1604⟩ Presentation of Aerodynamic Particle Size Distribution (APSD) Measurement Data for Orally Inhaled Drug Products PF 48(1)	Commenting Open	03-Jan-2022 to 31-Mar- 2022	PF 48(1)	Draft	01-Mar-2022

## Feedback and Q&A

usp

- What categories did we miss?
  - Critical comments
- What do you want to see next?



# Thank You



The standard of trust